A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

Abstract Background Ample evidence indicates the efficacy of serotonin type 3 (5-HT3) receptor antagonists in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Mirtazapine is an atypical antidepressant with a well-known 5-HT3 receptor antagonist property. This stu...

Full description

Bibliographic Details
Main Authors: Alireza Khalilian, Davoud Ahmadimoghaddam, Shiva Saki, Younes Mohammadi, Maryam Mehrpooya
Format: Article
Language:English
Published: BMC 2021-02-01
Series:BioPsychoSocial Medicine
Subjects:
Irritable bowel syndrome
Diarrhea
5-hydroxytryptamine
Mirtazapine
Online Access:https://doi.org/10.1186/s13030-021-00205-2

Internet

https://doi.org/10.1186/s13030-021-00205-2

Similar Items